Springhill Fund Asset Management (Hk) CO LTD Akero Therapeutics, Inc. Transaction History

Springhill Fund Asset Management (Hk) CO LTD

$0
Q2 2025

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 13, 2025	SELL	$21.87 - $57.56 $2.87 Million - $7.56 Million	-131,275 Reduced 86.82%	19,925 $807 Million
Q4 2024 Feb 13, 2025	BUY	$26.75 - $35.28 $4.04 Million - $5.33 Million	151,200 New	151,200 $4.21 Billion

Others Institutions Holding AKRO

# of Institutions

277

Shares Held

85.6M

Call Options Held

Put Options Held

720K

Rtw Investments, LP New York, NY

7.42M
Shares

$356 Million
4.92% of portfolio
Janus Henderson Group PLC London, X0

7.07M
Shares

$340 Million
0.16% of portfolio
Wellington Management Group LLP Boston, MA

5.94M
Shares

$285 Million
0.05% of portfolio
Black Rock Inc. New York, NY

5.59M
Shares

$268 Million
0.0% of portfolio
General Atlantic LLC New York, NY

5.23M
Shares

$251 Million
7.15% of portfolio

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.23B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Springhill Fund Asset Management (Hk) CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Springhill Fund Asset Management (Hk) CO LTD with notifications on news.

Account